I am a
Home I AM A Search Login

Papers of the Week


Open Heart



Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI).


Anstensrud A K, Woxholt S, Sharma K, Broch K, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås J K, Hopp E, Kleveland O, Stensæth K H, Opdahl A, Kløw N-E, Seljeflot I, Andersen G Ø, Wiseth R, Aukrust Pål, Gullestad L
Open Heart. 2019; 6(2):e001108.
PMID: 31673391.


Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 inhibition by tocilizumab attenuates systemic inflammation and troponin T-release in patients with acute non-ST elevation MI (NSTEMI). Experimental studies suggest that IL-6 inhibition can limit infarct size through anti-inflammatory mechanisms, but this has not been tested in clinical studies. With the essing the effect of nti–6 treatment in (ASSAIL-MI) trial, we aim to examine whether a single administration of the IL-6 receptor antagonist tocilizumab can increase myocardial salvage in patients with acute ST-elevation MI (STEMI).